Advertisement

Haemostasis pp 321-333 | Cite as

Nijmegen-Bethesda Assay to Measure Factor VIII Inhibitors

  • Elizabeth Duncan
  • Margaret Collecutt
  • Alison Street
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 992)

Abstract

Hemophilia A is an inherited bleeding disorder caused by a deficiency of factor VIII coagulant activity (FVIII:C). Patients are treated with infusions of either plasma-derived or recombinant factor VIII. However, some patients develop inhibitory antibodies (inhibitors) to infused factor VIII which render it ineffective. The original Bethesda method was developed to standardize measurement of inhibitors in a factor VIII neutralization assay. One Bethesda unit is defined as that amount of inhibitor that results in 50% residual FVIII:C activity of a defined test mixture. In the Nijmegen modification of the original Bethesda method, the pH and the protein concentration of the test mixture is further standardized. As a result, the FVIII:C in the test mixture is less prone to artifactual deterioration and the test has improved specificity. Even with a standardized procedure a number of factors can affect the performance of the test and it is important for laboratory staff to be aware of their impact on the result outcome.

Key words

Factor VIII Hemophilia Coagulation Inhibitor 

References

  1. 1.
    Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594–598PubMedCrossRefGoogle Scholar
  2. 2.
    Scharrer I, Neutzling O (1993) Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagul Fibrinolysis 4:753–758PubMedGoogle Scholar
  3. 3.
    Wright J, Paisley S (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9:418–435CrossRefGoogle Scholar
  4. 4.
    Hay CRM (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 4:558–563PubMedCrossRefGoogle Scholar
  5. 5.
    Oldenburg J, El-Maarri O, Schwaab R (2002) Inhibitor development in correlation to factor VIII genotypes. Haemophilia 8(Suppl 2):23–29PubMedCrossRefGoogle Scholar
  6. 6.
    Peerlink K, Hermans C (2006) Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 12:579–590CrossRefGoogle Scholar
  7. 7.
    Hay CRM, Brown S, Collins PW, Keeling DM, Liesner R (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organization. Brit J Haematol 133:591–605CrossRefGoogle Scholar
  8. 8.
    Dimichele DM (2006) Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. Haemophilia 12(Suppl 6):37–42PubMedCrossRefGoogle Scholar
  9. 9.
    Kasper CK, Aledort LM, Counts RB, Edson JR, Frantantoni J, Green D et al (1975) A more uniform measurement of factor VIII inhibitors. Thrombos Diath Haemorrh 34:869–872Google Scholar
  10. 10.
    Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 73:247–251PubMedGoogle Scholar
  11. 11.
    Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I, and the Association of Haemophilia Centre Directors of Canada (1998) A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population in Canada. Thromb Haemost 79:872–875PubMedGoogle Scholar
  12. 12.
    Gadarowski JJ, Czapek EE, Ontiveros JD, Pedraza JL (1988) Modification of the Bethesda assay for factor VIII and IX inhibitors to improve efficiency. Acta Haematol 80:134–138PubMedCrossRefGoogle Scholar
  13. 13.
    Hay CRM, Baglin TP, Collins PW, Hill FGH, Keeling DM (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Brit J Haematol 111:78–90CrossRefGoogle Scholar
  14. 14.
    Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O et al (2003) Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 101:4783–4788PubMedCrossRefGoogle Scholar
  15. 15.
    Favaloro EJ, Posen J, Ramakrishna R, Soltani S, McRae S, Just S et al (2004) Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 15:637–647PubMedCrossRefGoogle Scholar
  16. 16.
    Gatti L, Mannucci PM (1984) Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost 51:379–384PubMedGoogle Scholar
  17. 17.
    Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV (2003) Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with haemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 1:2548–2553PubMedCrossRefGoogle Scholar
  18. 18.
    Verbruggen B, Novakova I, van Heerde W (2009) Detecting and quantifying functional inhibitors in haemostasis. In: Kitchen S, Olson JD, Preston FE (eds) Quality in laboratory haemostasis and thrombosis, 1st edn. Blackwell Publishing, Oxford, Chapter 20Google Scholar
  19. 19.
    Kasper CK (1995) Laboratory diagnosis of factor VIII inhibitors. In: Kessler C, Garvey MB, Green D, Kasper C, Lusher J (eds) Acquired haemophilia, 2nd edn. Excerpta Medica, Princeton, NJ, Chapter 2Google Scholar
  20. 20.
    Goldsmith J (1993) Diagnosis of factor VIII versus nonspecific inhibitors. Semin Haematol 30(Suppl 1):3–6Google Scholar
  21. 21.
    Ling M, Duncan EM, Rodgers SE, Somogyi AA, Crabb GA, Street AM, Lloyd JV (2001) Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. Brit J Haematol 114:861–867CrossRefGoogle Scholar
  22. 22.
    Sahud MA (2000) Laboratory diagnosis of inhibitors. Semin Thromb Hemostas 26:195–203CrossRefGoogle Scholar
  23. 23.
    Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novakova I (2001) The type of factor deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors. Thromb Haemost 86:1435–1439PubMedGoogle Scholar
  24. 24.
    Verbruggen B, van Heerde W, Novakova I, Lillicrap D, Giles A (2002) A 4% solution of bovine serum albumin may be used in the place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 88:362–364PubMedGoogle Scholar
  25. 25.
    Reber G, Aurousseau MH, Dreyfus M, Delahousse B, Caron C, Trzeciack MC et al (1999) Inter-laboratory variability of the measurement of low titer factor VIII:C inhibitor in haemophiliacs: improvement by the Nijmegen modification of the Bethesda assay and the use of common lyophilized plasmas. Haemophilia 5:292–293PubMedCrossRefGoogle Scholar
  26. 26.
    Favaloro EJ, Bonar R, Duncan E, Earl G, Low J, Aboud M et al (2006) Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 96:73–78PubMedGoogle Scholar
  27. 27.
    Ewing NP, Kasper CK (1982) In Vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol 77:749–752PubMedGoogle Scholar
  28. 28.
    Keeling D, Beavis J, Sukhu K (2005) A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B. Brit J Haematol 128:885CrossRefGoogle Scholar
  29. 29.
    Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P et al (1996) High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Brit J Haematol 93:688–693CrossRefGoogle Scholar
  30. 30.
    White GC (1994) Factor VIII inhibitor assay: quantitative and qualitative assay limitations and development needs. Semin Haematol 31(Suppl 4):6–10Google Scholar
  31. 31.
    Blanco AN, Peirano AA, Grosso SH, Gennari LC, Bianco RP, Lazzari MA (2002) A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant. Haematologica 87:271–278PubMedGoogle Scholar
  32. 32.
    Manco-Johnson MJ, Nuss R, Jacobson LJ (2000) Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med 136:74–79PubMedCrossRefGoogle Scholar
  33. 33.
    Keeney M, Allan DS, Lohmann RC, Chin Yee IH (2005) Effect of recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX. Lab Haematol 11:118–123CrossRefGoogle Scholar
  34. 34.
    Barrow RT, Lollar P (2006) Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost 4:2223–2229PubMedCrossRefGoogle Scholar
  35. 35.
    Lloyd JV, Duncan EM, Street AM, Maxwell EL, Berry E, Rowell J et al (1997) Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand. Aust N Z J Med 27:658–664PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press 2013

Authors and Affiliations

  • Elizabeth Duncan
    • 1
  • Margaret Collecutt
    • 2
  • Alison Street
    • 3
  1. 1.Division of HaematologyInstitute of Medical and Veterinary ScienceAdelaideAustralia
  2. 2.Alfred Pathology ServiceThe Alfred HospitalMelbourneAustralia
  3. 3.Department of HaematologyThe Alfred HospitalMelbourneAustralia

Personalised recommendations